<div id="readability-page-1"><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.83 by $0.21, FiscalAI reports. The company had revenue of $805.00 million for the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.82 earnings per share.  West Pharmaceutical Services updated its FY 2026 guidance to 7.850-8.200 EPS.</p><ul><li>3 Dividend Champions with room for dividend growth</li></ul><p>Here are the key takeaways from West Pharmaceutical Services' conference call:</p><ul>   <li><strong>Q4 outperformance and cash generation.</strong> Revenues of $805M and adjusted EPS of $2.04 beat expectations, with free cash flow up ~70% for the year, strengthening the company’s liquidity and financial flexibility.</li>   <li><strong>2026 guidance indicates continued growth and margin expansion.</strong> Management guided to 5%–7% organic revenue growth, adjusted EPS $7.85–$8.20, and &gt;100 bps of margin expansion, signaling confidence in underlying demand.</li>   <li><strong>HVP components remain the primary growth engine.</strong> High-value product components (48% of sales) grew strongly (15% in Q4), driven by GLP-1s, Annex 1 upgrades, and biologics/biosimilars, and the company launched the Synchrony syringe platform and began Dublin drug‑handling commercialization.</li>   <li><strong>Near-term capacity constraints and operational disruptions.</strong> Management said demand currently outstrips supply (notably in Europe), requiring continued capacity and labor additions, and a temporary Arizona water-main incident hurt contract manufacturing results in Q4.</li>   <li><strong>SmartDose 3.5 divestiture expected mid‑year.</strong> The planned sale (previously ~ $55M of H2 2025 sales) aligns with strategy to focus on HVP components and should be neutral-to-positive for margins, but reduces device revenue exposure and is a near-term model adjustment.</li> </ul><h2>West Pharmaceutical Services Price Performance</h2><p>Shares of West Pharmaceutical Services stock traded down $4.38 during midday trading on Thursday, reaching $241.79. The company had a trading volume of 1,462,484 shares, compared to its average volume of 1,111,565. The stock has a fifty day simple moving average of $262.32 and a 200 day simple moving average of $261.73. West Pharmaceutical Services has a 1-year low of $187.43 and a 1-year high of $322.34. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $17.39 billion, a price-to-earnings ratio of 35.69, a price-to-earnings-growth ratio of 3.32 and a beta of 1.18. </p><h2>West Pharmaceutical Services Dividend Announcement</h2><ul><li>What Factors Will Drive S&amp;P 500 Performance This Year?</li></ul><p>The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 4th. Stockholders of record on Wednesday, January 28th were paid a $0.22 dividend. The ex-dividend date was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.4%. West Pharmaceutical Services's dividend payout ratio (DPR) is 13.04%. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts have recently weighed in on WST shares. Evercore cut their price objective on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday, February 3rd. Zacks Research raised shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, January 21st. Jefferies Financial Group  reiterated a &#34;buy&#34; rating and set a $295.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday. Morgan Stanley assumed coverage on shares of West Pharmaceutical Services in a report on Monday, December 1st. They issued an &#34;equal weight&#34; rating and a $285.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft  set a $345.00 target price on West Pharmaceutical Services and gave the company a &#34;buy&#34; rating in a research note on Friday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued  a Buy rating and three have assigned  a Hold rating to the company. According to data from MarketBeat.com, West Pharmaceutical Services  has an average rating of &#34;Buy&#34; and a consensus target price of $326.22.</p><ul><li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li></ul><p><b>Get Our Latest Research Report on West Pharmaceutical Services</b></p><h2>Hedge Funds Weigh In On West Pharmaceutical Services</h2><p>Hedge funds have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC bought a new stake in  West Pharmaceutical Services during the second quarter worth about $25,000.  MUFG Securities EMEA plc bought a new position in shares of  West Pharmaceutical Services during the 2nd quarter worth about $47,000.  State of Wyoming bought a new stake in  West Pharmaceutical Services during the 2nd quarter worth approximately $49,000.  Meeder Asset Management Inc. increased its position in shares of  West Pharmaceutical Services by 1,023.5% during the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier's stock valued at $53,000 after acquiring an additional 174 shares during the last quarter.  Finally, Darwin Wealth Management LLC bought a new position in  West Pharmaceutical Services during the second quarter valued at $75,000. Institutional investors and hedge funds own  93.90% of the company's stock. </p><h2>Key Stories Impacting West Pharmaceutical Services</h2><p>Here are the key news stories impacting West Pharmaceutical Services this week:</p><ul>   <li><span>Positive Sentiment: </span>Q4 results beat expectations — West reported EPS of $2.04 (vs. ~$1.83 consensus) and revenue of $805M (above estimates), with revenue up ~7.5% year‑over‑year and healthy margins. Strong underlying demand for its injectable components drove the beat. <i></i><span>West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say</span></li>    <li><span>Positive Sentiment: </span>Company raised FY‑2026 guidance — management set EPS guidance of $7.85–$8.20 (above consensus) and revenue guidance of ~$3.2–3.3B, signalling continued strong demand for proprietary products (cartridges, syringes). This is the main fundamental positive supporting the stock. <i></i><span>West Pharma forecasts 2026 profit above estimates on strong demand for drug components</span></li>    <li><span>Neutral Sentiment: </span>Official company materials and investor access — West posted its press release, slide deck and hosted a conference call, which should give more detail on margin drivers and segment trends for investors to parse. <i></i><span>View Slide Deck (Company)</span></li>    <li><span>Neutral Sentiment: </span>Brokerage view remains constructive — consensus analyst ratings stayed positive (consensus Buy), so longer‑term sell‑side sentiment hasn’t notably weakened after the report. <i></i><span>West Pharmaceutical Services, Inc. Receives Consensus Rating of &#34;Buy&#34; from Brokerages</span></li>    <li><span>Negative Sentiment: </span>Short interest rose into late January (≈33% increase month‑over‑month to ~3.6% of shares), which can amplify downward pressure/volatility if investors step up bearish activity. (Investors should monitor updated short statistics.)</li>    <li><span>Negative Sentiment: </span>Immediate market reaction shows profit‑taking and a reversal after an initial post‑earnings pop — some outlets reported a &gt;5% intraday jump after results, followed by a pullback as traders locked gains; technical/valuation considerations (relatively rich P/E) likely contributed to selling. <i></i><span>West Pharma gains more than 5% after Q4 earnings outperform</span> <i></i><span>Stock underperforms peers despite daily gains</span></li> </ul><h2>West Pharmaceutical Services Company Profile</h2> (Get Free Report)<p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.  </p><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p><h2>Read More</h2><ul><li>Five stocks we like better than West Pharmaceutical Services</li><li>USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.</li><li>The DoD just got a new drone supplier</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>When to buy gold (mathematically)</li><li>Think You Missed Silver? You’re Wrong. Here’s Why.</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>West Pharmaceutical Services (NYSE:WST) reported quarterly earnings of $2.04 EPS, exceeding estimates by $0.21. Revenue reached $805 million, surpassing expectations of $795.70 million, with a year-over-year growth of 7.5%. The company updated its FY 2026 guidance to $7.85-$8.20 EPS, indicating continued growth. Despite operational challenges, including capacity constraints, management remains confident in demand. The stock traded down to $241.79, with a market cap of $17.39 billion. Analysts have mixed ratings, with an average target price of $326.22, reflecting a generally positive outlook.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

West Pharmaceutical

iShares US Medical Devices

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS